Loading…
Loading…
The Commission cleared, under EU State aid rules, a €400 million German measure compensating Sanofi-Aventis Deutschland GmbH for the net cost of providing a service of general economic interest (SGEI): guaranteeing German patients' access to human insulin and insulin analogues against production and supply bottlenecks. Rather than a conventional investment grant, the aid is structured as public-service compensation tied to binding output and capacity commitments — Sanofi must build a new insulin factory at its existing Industriepark Frankfurt-Höchst site by end-2032 and sustain annual production of at least 1.1 tonnes of insulins there through 2042.
The decision follows the Commission's March 2025 Critical Medicines Act proposal, which frames onshoring of essential-drug manufacturing (including insulin, antibiotics, painkillers) as a supply-chain-resilience priority after repeated EU shortage episodes.
single manufacturer for a public-service obligation, rather than a plain investment grant, is a structure the Commission can reuse for other shortage-prone essential medicines (antibiotics, painkillers) named in the Critical Medicines Act framing.
EU insulin capacity to a single Sanofi site for over 15 years, reducing near-term EU exposure to non-EU insulin supply disruption.
Pharmaceutical-Strategy-linked state aid:** continues a pattern of company-specific EU pharma manufacturing clearances distinct from the semiconductor Chips Act precedents.
a lump sum, and whether it is subject to clawback if Sanofi fails to meet the 1.1-tonne annual production floor.
production sites receive or seek comparable SGEI-structured aid.
million compensation — the press release does not disclose the plant's full construction budget.